U.S. markets closed
  • S&P Futures

    3,799.25
    +8.75 (+0.23%)
     
  • Dow Futures

    30,871.00
    +43.00 (+0.14%)
     
  • Nasdaq Futures

    13,045.00
    +59.50 (+0.46%)
     
  • Russell 2000 Futures

    2,145.50
    -1.80 (-0.08%)
     
  • Crude Oil

    53.12
    +0.14 (+0.26%)
     
  • Gold

    1,843.80
    +3.60 (+0.20%)
     
  • Silver

    25.41
    +0.09 (+0.36%)
     
  • EUR/USD

    1.2142
    +0.0009 (+0.07%)
     
  • 10-Yr Bond

    1.0920
    -0.0050 (-0.46%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3639
    +0.0005 (+0.04%)
     
  • USD/JPY

    103.8500
    -0.0420 (-0.04%)
     
  • BTC-USD

    36,300.51
    +144.86 (+0.40%)
     
  • CMC Crypto 200

    720.56
    +5.37 (+0.75%)
     
  • FTSE 100

    6,712.95
    -7.70 (-0.11%)
     
  • Nikkei 225

    28,590.14
    -43.32 (-0.15%)
     

A Look At The Fair Value Of Cantel Medical Corp. (NYSE:CMD)

Simply Wall St
·6 min read

In this article we are going to estimate the intrinsic value of Cantel Medical Corp. (NYSE:CMD) by estimating the company's future cash flows and discounting them to their present value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. There's really not all that much to it, even though it might appear quite complex.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Cantel Medical

What's the estimated valuation?

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) estimate

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

US$60.4m

US$110.2m

US$138.0m

US$163.4m

US$185.4m

US$204.2m

US$220.0m

US$233.4m

US$244.9m

US$255.0m

Growth Rate Estimate Source

Analyst x2

Analyst x1

Est @ 25.24%

Est @ 18.33%

Est @ 13.5%

Est @ 10.12%

Est @ 7.75%

Est @ 6.09%

Est @ 4.93%

Est @ 4.12%

Present Value ($, Millions) Discounted @ 8.9%

US$55.5

US$92.9

US$107

US$116

US$121

US$122

US$121

US$118

US$114

US$109

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$1.1b

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.2%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 8.9%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$255m× (1 + 2.2%) ÷ (8.9%– 2.2%) = US$3.9b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$3.9b÷ ( 1 + 8.9%)10= US$1.7b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$2.7b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of US$54.6, the company appears about fair value at a 17% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

dcf
dcf

Important assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Cantel Medical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.9%, which is based on a levered beta of 1.112. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Looking Ahead:

Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Cantel Medical, there are three further aspects you should further research:

  1. Risks: Every company has them, and we've spotted 4 warning signs for Cantel Medical (of which 1 is a bit unpleasant!) you should know about.

  2. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for CMD's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.

  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.